

## Homolog Recombination Deficiency, Genetics in Ovarian Cancer

Guest Editor:

**Prof. Dr. Amit Manulal Oza**

University Health Network  
University of Toronto, Toronto,  
Canada

Deadline for manuscript  
submissions:

**closed (30 June 2021)**


### Message from the Guest Editor

Dear Colleagues,

Contemporary ovarian cancer management incorporates comprehensive approaches to BRCA1/2 and genomic testing to identify the potential for inherited risk (and hence prevention for family members) as well as prediction of therapeutic outcome, most notably with PARP inhibitors. Emerging research on resistance mechanisms will help to guide the potential for future precision therapy to overcome this, or at least avoid futile therapy. This Special Issue will go beyond examining the role of BRCA1/2 and HRD in ovarian cancer and delve into key areas of development in preclinical and clinical domains. Current research is being conducted to advance precise therapeutic approaches (surgical, radiation, and drug development), disease monitoring technologies, equitable access to testing, and therapeutic access to agents such as PARPi and to identify issues related to the impact of treatment chronicity on quality of life.

Prof. Dr. Amit Manulal Oza  
Guest Editor





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)